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Pulmonary embolism (PE) is traditionally
treated in hospital. Growing evidence from non
randomized prospective studies suggests that a
substantial proportion of patients with non-mas-
sive PE might be safely treated in the outpatient
setting using low molecular weight heparins.
Based on this evidence, professional societies
started to recommend outpatient care for selected
patients with non-massive PE. Despite these rec-
ommendations, outpatient treatment of non-mas-
sive PE appears to be uncommon in clinical prac-
tice. The major barriers to PE outpatient care are,
firstly, the uncertainty as how to identify low risk
patients with PE who are candidates for outpa-
tient care and secondly the lack of high quality ev-
idence from randomized trials demonstrating the
safety of PE outpatient care compared to tradi-
tional inpatient management. Also, although clin-
ical prognostic models, echocardiography and
cardiac biomarkers accurately identify low risk
patients with PE in prospective studies, the bene-
fit of risk stratification strategies based on these
instruments should be demonstrated in prospec-
tive management studies and clinical trials before
they can be implemented as decision aids to guide
PE outpatient treatment. Before high quality evi-
dence documenting the safety of an outpatient
treatment approach is published, outpatient man-
agement of non-massive PE cannot be generally
recommended.
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Summary
Pulmonary embolism (PE) is a common med-
ical condition, with an incidence of 23–69 new
cases per 100000 persons per year. [1, 2] The
most important prognostic factor related to PE is
the haemodynamic status of the patient at admis-
sion. Massive PE, defined by the presence of sys-
temic hypotension or shock, accounts for 5% of
all cases of PE and has high short term mortality
around 27%. [3] Patients with massive PE need
intensive care and thrombolytic therapy are usu-
ally recommended. [4] Haemodynamically stable,
non-massive PE accounts for 95% of all cases of 
PE and has a much lower short term mortality of 
4–8%. [3, 5, 6] PE is traditionally treated in hospi-
tal, even if the patient has non-massive PE with 
few symptoms. Arguments for treating non-massive
PE in the hospital rather than in the outpatient
setting are that potentially fatal complications
such as clinical deterioration due to recurrent 
PE or anticoagulation related major bleeding
could be detected and treated earlier in hospital.
However, growing evidence from prospective
studies suggests that selected patients with non-
massive PE may be safely treated in the outpatient
setting using low molecular weight heparin ad-
ministered by patients, family members or visiting
nurses (table 1). Based on this evidence, several
professional societies issued recommendations for
PE-related outpatient care. [7–9] In 2003, the
British Thoracic Society guidelines suggested
outpatient care for “clinically stable” patients with
PE but the strength of this recommendation was
low (grade C). [7] According to a practice guide-
line from the American College of Physicians
published in 2007, outpatient treatment of deep
vein thrombosis (DVT), and possibly PE, is safe
for “carefully selected” patients and should be
considered if the required support services are in
place. [8] Finally, the 2008 European Society of
Cardiology guidelines suggested considering low
risk patients with PE, i.e., those without principal
PE-related risk factors, for early discharge if
proper outpatient care and anticoagulant treat-
ment can be provided. [9] It has been estimated
that up to 50% of patients with PE could be safely
treated in an outpatient setting. [10]
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Table 1
Prospective studies of outpatient treatment for pulmonary embolism.
Study No of Exclusion criteria for outpatient care Intervention Outcomes 
patients at 3–13 months
Kovacs 2000 [43] 81 Active bleeding or high bleeding risk, low compliance, renal failure, Dalteparin 200 IU/kg sc VTE recurrence: 6.2%
haemodynamic instability, requirement of oxygen, severe pain requiring once daily Major bleeding: 1.2%
parenteral narcotics, or hospitalisation necessary for other reasons Overall mortality: 4.9%
Beer 2003 [44] 43 Geneva Prognostic Score >2, contraindication to anticoagulants, Nadroparin 171 IU/kg sc VTE recurrence: 2.3%
drug addiction, non-compliance, psychiatric conditions, body once daily Major bleeding: 0%
weight >110/kg, renal failure, thrombocytopenia, concomitant Overall mortality: 0%
thrombolysis, prior treatment with oral anticoagulants, or patients 
presenting on weekends
Wells 2005 [45] 90 Active bleeding or high bleeding risk, no fixed address, history Dalteparin 200 IU/kg VTE recurrence: 2.2%
of heparin-induced thrombocytopenia, renal failure, arterial or Tinzaparin 175 U/kg sc Major bleeding: 0% 
hypotension, hypoxaemia, severe pain requiring intravenous analgesia, once daily Overall mortality: 3.3%
or hospitalisation necessary for other reasons
Siragusa 2005* [46] 32 Poor clinical condition, other illness requiring hospitalisation, Unspecified low-molecular- VTE recurrence: 5.6%
poor compliance, active bleeding or high bleeding risk, renal failure, weight heparin sc once or Major bleeding: 2.8%
acute anaemia, or pain requiring parenteral narcotics twice daily. Overall mortality: 30.6%
Olsson 2006 [16] 100 Extensive PE based on lung scintigraphy or other reasons necessitating Tinzaparin 175 U/kg sc VTE recurrence: 0%
hospitalisation (e.g., intensive pain, status post surgery, active bleeding) once daily in a patient hotel Major bleeding: 0%
close to the hospital Overall mortality: 0%
Davies 2007 [47] 156 Admission necessary for other medical reason, additional monitoring Tinzaparin 175 U/kg sc VTE recurrence: 0%
required, history of prior PE, concomitant major DVT, bleeding once daily Major bleeding: 0%
disorders or active bleeding, poor compliance, or patient preference Overall mortality: 0%
VTE = venous thromboembolism; PE = pulmonary embolism; DVT = deep vein thrombosis.
*Study enrolled patients with cancer only.
Benefits of PE outpatient care
The potential benefits of PE outpatient care
over traditional inpatient care include an im-
provement in health-related quality of life and in-
creased physical activity and social functioning.
[11, 12] Moreover, the implementation of outpa-
tient treatment strategies is likely to reduce the
length of hospital stay and may result in substan-
tial cost savings. [13] We used projections from a
prior cost-effectiveness analysis to estimate the
potential economic impact of outpatient treat-
ment of PE in Switzerland. Assuming a cost dif-
ference of $ 4500 between inpatient and outpa-
tient treatment of PE and an annual PE incidence
of 3,133 cases, over $ 7 million per year could be
saved in Switzerland if 50% of PE patients were
treated as outpatients. [13, 14] Many hospitals
could readily employ the existing infrastructure
used to treat patients with DVT as outpatients in
low risk patients with PE (e.g., anticoagulation
clinics and outpatient treatment protocols). The
projected cost savings as a result of outpatient care
of PE is likely to far outweigh the implementation
costs for any outpatient treatment strategy.
Barriers to PE outpatient care
To our knowledge, there are no published
data on the utilisation of PE outpatient care but
reports from Europe and Australia suggest that
outpatient treatment of non-massive PE is un-
common. [15–17] Two major barriers exist to PE
outpatient care. Firstly, there is uncertainty as to
how to identify low risk patients with non-massive
PE who may be safely treated in the outpatient
setting. The eligibility criteria of previous studies
of PE outpatient treatment were heterogeneous
and vague (e.g., “comorbid conditions that neces-
sitate hospitalisation”) and are difficult to repro-
duce with uniformity or confidence (table 1). Also,
practice guidelines recommending PE outpatient
care fail to specify the details as to how to select
low risk patients with PE who could be safely
treated as outpatients. [7–9] The lack of prognos-
tic criteria to identify low risk patients with PE
and physicians’ insecurity in assessing baseline
risk to the patient is reflected by the large varia-
tion in length of hospital stay for PE and may
have a negative impact on patient outcomes. [18]
A retrospective cohort study demonstrated that
after adjustment for patient and hospital factors,
patients with a relatively short hospital stay of
four days or less had a significantly higher 30-day
mortality that those with a typical length of stay of
five to eight days (OR 1.55, 95% CI: 1.22–2.00).
[18] These results suggest that physicians may in-
appropriately select patients with PE for early dis-
charge who are at increased risk of complications. 
The second barrier is the limited evidence
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demonstrating the safety of PE outpatient treat-
ment. Existing studies of outpatient treatment for
PE are based on relatively small sample sizes.
Only 156 patients were enrolled in the largest
study to date (table 1). None of these studies 
compared outpatient to inpatient treatment in 
a randomized trial. In a recent survey among 
71 emergency physicians at three U.S. university
hospitals, only eight out of 464 PE episodes (2%)
were targeted for outpatient treatment during the
previous twelve months, despite the availability of
adequate outpatient services utilised for patients
with DVT (Aujesky D, unpublished data). Never-
theless, the majority (73%) of these emergency
physicians reported a willingness to consider this
treatment option if high quality empiric data 
supporting the effectiveness and safety of the out-
patient management of PE were available. The
historical example of DVT demonstrates that 
evidence from randomized trials has the potential
to change clinical practice. Before 1996, DVT was
mostly managed in hospital. After the publication
of clinical trials demonstrating the safety of DVT
outpatient care compared to traditional inpatient
care, [11, 19] outpatient treatment of DVT was
rapidly adopted in clinical practice. [20]
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Risk stratification of patients with PE
As the  subjective judgment of the physician
may fail to identify patients with PE who have a
good prognosis and who may be safely treated in
the outpatient setting, several objective prognos-
tic instruments may help physicians to identify
low risk patients with PE who are potential candi-
dates for outpatient care: clinical prognostic mod-
els, imaging procedures and cardiac biomarkers.
Clinical prognostic models
The Geneva Prognostic Score (GPS) is based
on six clinical, laboratory and ultrasonographic
variables to predict the combined adverse out-
come of death, recurrent venous thromboem-
bolism and major bleeding episodes during the
first three months following the index PE (table
2). [21] Low risk patients based on the GPS (≤2
points) have a low rate of adverse outcomes (2.2–
5.0%), with a sensitivity of 58–85% and a negative
predictive value of 95–98% for predicting adverse
outcomes. [21, 22]
The most extensively validated clinical prog-
nostic model is the Pulmonary Embolism Severity
Index (PESI) that accurately stratifies patients
into five risk classes (I–V) with increasing risk of
all cause short term mortality, ranging from 1.1%
in class I to 24.5% in class V (table 3). [23] The
PESI comprises eleven routinely available clinical
parameters without any need for ultrasonography
or laboratory studies. [23] Patients in risk classes I
and II have a 30-day all cause mortality of 0.9–
2.6% only and are considered low risk. [23, 24]
When dichotomized as low (classes I/II) versus
higher risk (classes III–V), the PESI has a sensitiv-
ity of ≥90% and a negative predictive value of 98–
100% for predicting mortality. [24, 25]
Jiménez et al. retrospectively compared the
prognostic accuracy of the GPS and the PESI in
599 patients with PE. [25] The GPS identified a
significantly higher proportion of patients with
PE as low risk than the PESI (84% vs 36%, P
<0.001). However, low-risk patients based on the
GPS had a significantly higher 30 day mortality
(5.6% vs 0.9%, P <0.001), resulting in a lower sen-
sitivity for overall mortality compared to the PESI
(35% vs 95%). The proportions of low risk pa-
tients who had any adverse outcome at 30 days
(death or non fatal recurrent venous thromboem-
bolism or major bleeding) were similar for both
scores. Because both scores were primarily devel-
Predictors Points Assigned
Cancer +2
Heart failure +1
Previous deep vein thrombosis +1
Systolic blood pressure <100 mm Hg +2
Arterial blood gas analysis with PaO2 <8 kPa +1
(60 mm Hg)
Proximal deep vein thrombosis shown +1
by ultrasound
A total point score of two points or less defines low risk patients.
Table 2
The Geneva 
Prognostic Score.
Table 3
The Pulmonary 
Embolism Severity
Index.
Predictors Points assigned
Demographic characteristics
Age, per year Age, in years
Male sex +10
Comorbid illnesses
Cancer* +30
Heart failure +10  
Chronic lung disease +10  
Clinical findings   
Pulse ≥110/minute +20  
Systolic blood pressure <100 mm Hg +30  
Respiratory rate ≥30/minute +20  
Temperature <36 ºC +20  
Altered mental status† +60  
Arterial oxygen saturation <90%‡ +20  
A total point score for a given patient is obtained by summing 
the patient’s age in years and the points for each applicable predic-
tor. Points assignments correspond with the following risk classes:
≤65 class I; 66–85 class II; 86–105 class III; 106–125 class IV; and
>125 class V. Patients in risk classes I and II are defined as low-risk.
* Defined as a history of cancer or active cancer.
† Defined as disorientation, lethargy, stupor, or coma.
‡ With and without the administration of supplemental oxygen.
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oped to identify low risk patients with PE, their
positive predictive value for predicting mortality
was low (<20%).
Imaging
A meta-analysis including five prospective
studies of haemodynamically stable patients with
PE demonstrated that patients without echocar-
diographic right ventricular (RV) dysfunction, de-
fined by a RV wall hypokinesis, RV dilatation or
an increased right/left ventricular end diastolic
diameter ratio, had a short term all cause mortal-
ity of 3% only. [26] Although patients without RV
dysfunction (56% of patients with PE) appear to
have a low mortality, whether such patients can be
safely treated as outpatients has not been prospec-
tively evaluated. Moreover, the practical use of
echocardiography for risk stratification is limited
by its operator dependence, cost, and lack of avail-
ability 24 hours a day in many hospitals.
Whether RV dilatation on spiral computed
tomography (CT) [26–29] and CT-based pul-
monary artery obstruction indices [30–34] are in-
dependent predictors of all cause mortality and
adverse events in patients with PE is still contro-
versial. The safety and efficiency of these CT-
based measures to identify low risk patients with
PE who are candidates for outpatient care has
never been prospectively validated. A recent study
demonstrated that concomitant deep vein throm-
bosis shown by ultrasonography is associated with
a fourfold increase in short-term overall mortal-
ity. [35] Whether ultrasonography can be used to
risk stratify patients with PE must be assessed in
further studies.
Cardiac biomarkers
The likely explanation for the release of car-
diac biomarkers in patients with more severe PE
is the development of RV microinfarctions (tro-
ponins) or cardiomyocyte stretch (brain natri-
uretic peptides). A meta-analysis including seven
prospective studies demonstrated that elevated
troponin I or T levels were significantly associ-
ated with short term all cause mortality in haemo-
dynamically stable patients with PE (OR 5.9, 95%
CI: 2.7–13.0) and that patients with normal tro-
ponin levels (21% of patients with PE) had a mor-
tality of only 2.3%. [36] A meta-analysis of 13
studies demonstrated that elevated brain natri-
uretic peptide levels (BNP or NT-pro-BNP) were
significantly associated with short term all cause
mortality in haemodynamically stable and unsta-
ble patients with PE (OR 7.6, 95% CI: 3.4–17.1)
[37]. Patients with normal BNP/NT-pro-BNP
levels (49% of patients with PE) had a mortality
of 1.7% only. [37] A meta-analysis including
haemodynamically stable patients showed similar
results. [26] Overall, patients with PE who have
normal cardiac biomarkers appear to have a low
risk of overall short term mortality. However, the
practical use of cardiac biomarkers in therapeutic
decision making is currently limited by a lack of
test standardisation (multiple assays and cut-off
points used) and the absence of clinical studies
demonstrating the safety of PE outpatient care
among patients with normal biomarkers levels.
Whether other novel cardiac biomarkers such
heart-type fatty acid binding protein or growth
differentiation factor-15 may be useful in identi-
fying low risk patients with PE who may be candi-
dates for outpatient care must be further evalu-
ated. [38, 39]
Combination of prognostic models, echocar-
diography and cardiac biomarkers
Several authors proposed outpatient care for
low risk patients identified using risk stratification
algorithms based on haemodynamic status, the
PESI, biomarkers and/or echocardiography. [40–
42] According to these algorithms, haemodynam-
ically stable low risk patients based on the PESI
(or those with normal echocardiographic RV
function or BNP/NT-pro BNP values) who have
normal troponin levels should be considered for
outpatient care. However, the safety and effi-
ciency of algorithms using echocardiography and
cardiac biomarkers to identify low risk patients
with PE has never been prospectively validated.
Whether outpatient treatment of haemodynami-
cally stable low risk patients based on the PESI is
as safe and efficient as inpatient care is currently
being evaluated in the international, randomized
Outpatient Treatment of Pulmonary Embolism
(OTPE) trial (NCT00425542). Results from this
trial will become available by late 2010.
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Conclusion
Outpatient care of patients with non-massive
PE using low-molecular weight heparins is logis-
tically feasible. However, it remains uncertain
how to best identify low risk patients with PE who
are candidates for outpatient care and whether
outpatient treatment for non-massive PE is really
as safe as traditional treatment in  hospital. Al-
though clinical prognostic models, echocardiogra-
phy and cardiac biomarkers accurately identified
low risk patients with PE in prospective studies,
the clinical impact of these prognostic measures
on the safety and efficiency of outpatient care re-
mains unclear. Any outpatient treatment strategy
based on these risk stratification tools should be
evaluated in prospective management studies and
clinical trials before such a strategy can be imple-
mented. Before high quality evidence document-
ing the safety of an outpatient treatment approach
becomes available, outpatient management of
non-massive PE must be decided on an individual
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basis and cannot be generally recommended. The
site of treatment decision must also consider psy-
chosocial contraindications to outpatient care.
For example, patients who use intravenous drugs
or who are alcoholic or unreliable or have severe
psychiatric conditions may require hospitalisation
to ensure adherence to treatment regardless of
the severity of their illness.
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